公开(公告)号：US12121586B2

公开(公告)日：2024-10-22

申请号：US17129251

申请日：2020-12-21

申请人： Genentech, Inc.

发明人： Patrick Koenig ,  Chingwei Vivian Lee ,  Karthikan Rajagopal ,  Amin Famili ,  Germaine Fuh

IPC分类号： C40B30/04 ,  A61K39/395 ,  A61K47/34 ,  A61K47/60 ,  A61K47/61 ,  C07K14/475 ,  C07K16/22 ,  C07K16/44 ,  C07K16/46 ,  C12N15/10 ,  C12N15/115 ,  A61K39/00

CPC分类号： A61K47/61 ,  A61K39/3955 ,  A61K47/34 ,  A61K47/60 ,  C07K14/475 ,  C07K16/22 ,  C07K16/44 ,  C07K16/468 ,  C12N15/1037 ,  C12N15/115 ,  C40B30/04 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/30 ,  C07K2319/31 ,  C12N2310/16

摘要： The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

公开(公告)号：US20240345048A1

公开(公告)日：2024-10-17

申请号：US18673492

申请日：2024-05-24

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Nathan L. MAO ,  Scott CARVER ,  Bernhard SCHILLING ,  Eric SHIERLY

IPC分类号： G01N30/88 ,  B01D15/20 ,  B01D15/32 ,  B01D15/36 ,  B01D15/38 ,  B01D15/42 ,  C07K1/16 ,  C07K14/475 ,  G01N30/02 ,  G01N30/56 ,  G01N30/74 ,  G01N30/86

CPC分类号： G01N30/88 ,  B01D15/3804 ,  B01D15/424 ,  C07K1/16 ,  G01N30/74 ,  G01N30/8651 ,  G01N30/8675 ,  B01D15/206 ,  B01D15/327 ,  B01D15/363 ,  C07K14/475 ,  G01N2030/027 ,  G01N30/56 ,  G01N2030/562 ,  G01N2030/889

摘要： The disclosure provides systems and methods useful for predicting or detecting a malfunction in a chromatography process in real-time. In some embodiments, the disclosure provides systems and methods for detecting an atypical profile in a process chromatogram in ion-exchange chromatography of a biologic product.

公开(公告)号：US12117448B2

公开(公告)日：2024-10-15

申请号：US16867560

申请日：2020-05-05

申请人： Children's Medical Center Corporation

发明人： Randolph Watnick

IPC分类号： G01N33/574 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  C07K14/475

CPC分类号： G01N33/574 ,  A61K38/1709 ,  A61K45/06 ,  C07K14/475 ,  A61K38/00 ,  A61K48/00 ,  G01N2800/56

摘要： The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

公开(公告)号：US20240269203A1

公开(公告)日：2024-08-15

申请号：US18545113

申请日：2023-12-19

申请人： Janssen Biotech, Inc.

发明人： David Baillat ,  Charles Drake ,  Steven R. Fuhrmann ,  Paul Harvilla ,  Sylvie Laquerre ,  Matthew Mulvey ,  Manuel Sepulveda ,  Raghavendra Shamanna ,  Ninkka Tamot ,  Kathryne Taylor ,  Douglas Yamada

IPC分类号： A61K35/763 ,  A61P35/00 ,  C07K14/475 ,  C07K14/54 ,  C07K16/28 ,  C12N15/86

CPC分类号： A61K35/763 ,  A61P35/00 ,  C07K14/475 ,  C07K14/5434 ,  C07K16/2818 ,  C07K16/2878 ,  C12N15/86 ,  C07K2317/75 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16671

摘要： Provided herein are oncolytic viruses including payload genes, encompassing genes that encode IL-12, FLT3L, CD40 agonists, and/or CTLA-4 antibodies. Also provided are expression cassettes, pharmaceutical compositions, and methods of treatment employing these viruses. Furthermore, expression cassettes and CD40 agonist molecules are also provided in this disclosure.

公开(公告)号：US12036279B2

公开(公告)日：2024-07-16

申请号：US17681342

申请日：2022-02-25

申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

发明人： Liang Deng ,  Stewart Shuman ,  Jedd Wolchok ,  Taha Merghoub ,  Weiyi Wang ,  Peihong Dai ,  Ning Yang

IPC分类号： C12N15/86 ,  A61K9/00 ,  A61K35/768 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/475 ,  C07K14/52 ,  C07K16/28

CPC分类号： A61K39/3955 ,  A61K9/0019 ,  A61K35/768 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/521 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/86 ,  A61K2039/505 ,  A61K2039/55522 ,  C07K2317/76 ,  C12N2710/24032 ,  C12N2710/24121 ,  C12N2710/24132 ,  C12N2710/24143 ,  A61K39/3955 ,  A61K2300/00

摘要： The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.

公开(公告)号：US20240228570A9

公开(公告)日：2024-07-11

申请号：US18491113

申请日：2023-10-20

申请人： ellennbe GmbH

发明人： Lydia Ellen Neumann

IPC分类号： C07K14/57 ,  A61K9/00 ,  A61K38/00 ,  A61K45/06 ,  A61M37/00 ,  A61P37/06 ,  C07K14/475 ,  C07K14/54 ,  C07K14/55

CPC分类号： C07K14/57 ,  A61K9/0019 ,  A61K45/06 ,  A61M37/0092 ,  A61P37/06 ,  C07K14/475 ,  C07K14/5406 ,  C07K14/55 ,  A61K38/00

摘要： The invention relates to an immunomodulatory substance(s) and/or a skin-conditioning agent for use in a method for treating and/or preventing an inflammatory disease, immunological disease and/or autoimmunological disease in a subject, wherein the method comprises a step (A) selected from one or more of: generating an accumulation of PBMCs within the skin, generating a vasodilation of the capillaries within the skin, generating an increased blood volume within the skin, generating an increased sO2 within the skin, generating an increased rHb within the skin, generating an increased temperature on the skin, generating a redness on the skin, administering conditioning energy to the skin, administering a skin-conditioning agent to the skin or administering PBMCs to the skin of the subject; and the method further comprises step (B) administering a first immunomodulatory substance(s) to the skin of the subject and/or step (C) administering a second immunomodulatory substance(s) to the skin of the subject.

公开(公告)号：US12025599B2

公开(公告)日：2024-07-02

申请号：US17953818

申请日：2022-09-27

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Nathan L. Mao ,  Scott Carver ,  Bernhard Schilling ,  Eric Shierly

IPC分类号： G01N30/88 ,  B01D15/20 ,  B01D15/32 ,  B01D15/36 ,  B01D15/38 ,  B01D15/42 ,  C07K1/16 ,  C07K14/475 ,  G01N30/02 ,  G01N30/56 ,  G01N30/74 ,  G01N30/86

CPC分类号： G01N30/88 ,  B01D15/3804 ,  B01D15/424 ,  C07K1/16 ,  G01N30/74 ,  G01N30/8651 ,  G01N30/8675 ,  B01D15/206 ,  B01D15/327 ,  B01D15/363 ,  C07K14/475 ,  G01N2030/027 ,  G01N30/56 ,  G01N2030/562 ,  G01N2030/889

摘要： The disclosure provides systems and methods useful for predicting or detecting a malfunction in a chromatography process in real-time. In some embodiments, the disclosure provides systems and methods for detecting an atypical profile in a process chromatogram in ion-exchange chromatography of a biologic product.

公开(公告)号：US20240209075A1

公开(公告)日：2024-06-27

申请号：US18333425

申请日：2023-06-12

申请人： UCB PHARMA S.A.

发明人： David G. Winkler ,  Jiye Shi ,  John Latham

IPC分类号： C07K16/22 ,  A61K47/64 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  G01N33/50 ,  G01N33/577 ,  G01N33/68

CPC分类号： C07K16/22 ,  A61K47/643 ,  A61K47/646 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  G01N33/6854 ,  C07K2317/76 ,  G01N33/50 ,  G01N33/577 ,  G01N33/68 ,  G01N33/6863 ,  G01N2333/4704

摘要： Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

公开(公告)号：US20240209047A1

公开(公告)日：2024-06-27

申请号：US18287249

申请日：2022-04-20

申请人： Vijay Krishna Raghunathan ,  Christopher J. Murphy ,  Nicholas L. Abbott

发明人： Vijay Krishna Raghunathan ,  Christopher J. Murphy ,  Nicholas L. Abbott

IPC分类号： C07K14/475 ,  A61K47/54 ,  A61P17/02 ,  A61K38/00

CPC分类号： C07K14/475 ,  A61K47/54 ,  A61P17/02 ,  A61K38/00

摘要： The present invention relates to the treatment of chronic wounds, and in particular to treatment of chronic wounds by via the use of growth factors conjugates that are immobilized in the wound. Specifically, the growth factor (GF) conjugates comprising a GF molecule covalently modified with a chemical moiety comprising a reactive functionality. Further disclosed arm GF molecules that are used for the conjugates and the chronic wounds can be treated using the GF conjugates.

公开(公告)号：US20240150460A1

公开(公告)日：2024-05-09

申请号：US18279014

申请日：2022-02-25

申请人： Shenghe (China) Biopharmaceutical Co., Ltd.

发明人： Jinhua ZHOU ,  Cailin ZHU ,  Chongbing WU ,  Xiaoling JIANG ,  Liusong YIN

IPC分类号： C07K16/28 ,  C07K14/475 ,  C07K14/495 ,  C07K14/535 ,  C07K14/54 ,  C07K14/555 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K16/2803 ,  C07K14/475 ,  C07K14/495 ,  C07K14/535 ,  C07K14/54 ,  C07K14/5421 ,  C07K14/5428 ,  C07K14/5443 ,  C07K14/555 ,  C07K16/28 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/303 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/569

摘要： The present invention discloses an anti-NKp30 single domain antibody capable of activating the release of cytokines from NK cells or γδT cells, and a nucleic acid encoding the anti-NKp30 single domain antibody. The present invention also discloses a multifunctional fusion protein comprising the anti-NKp30 single domain antibody and a composition thereof, and the use in drugs for the treatment, prevention or diagnosis of diseases.